Grünenthal Has Agreed to Acquire Stivarga from Bayer
The pharma firm will take over the cancer treatment in a deal valued at up to €375 million.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Do you trust that pharmaceutical acquisitions of existing drugs ultimately benefit patients?
Grünenthal has entered into an agreement to acquire the oral oncology drug Stivarga from Bayer AG for a maximum price of €375 million. The transaction, which includes the rights to the drug across more than 90 markets, remains subject to regulatory approvals.
Why it matters
The deal advances Grünenthal's ongoing strategy of absorbing established medical assets to utilize its existing commercial infrastructure. By adding this treatment, the company aims to sustain growth before the medication faces patent expirations in major regions later this decade.
Grünenthal reported €1.8 billion in 2025 revenue and has spent €2.6 billion on M&A since 2017. The acquired drug, Stivarga, has reached more than one million patients across 90 markets.
The players
Grünenthal
An Aachen-based pharmaceutical company that focuses on pain management and oncology through a strategy of acquiring established medical assets.
Bayer AG
A global life sciences company that develops pharmaceuticals and agricultural products, and which is currently divesting its oncology asset Stivarga.
The details
Grünenthal will assume commercial rights to the multikinase inhibitor, which is indicated for metastatic colorectal cancer and other tumor types. The acquisition is structured to integrate the product into Grünenthal's existing commercial platform, leveraging their current capabilities for mature assets. The transaction is expected to close by late 2026 or early 2027, provided that necessary regulatory conditions are met.
Timeline
Grünenthal began its current M&A investment strategy in 2017.
The company recorded €1.8 billion in revenue during 2025.
The acquisition agreement for Stivarga was announced on September 21, 2026.
The transaction is expected to close by late 2026 or early 2027.
Stivarga is projected to lose exclusivity in the EU in 2029 and the U.S. in 2030.
Market Landscape
This acquisition follows the pattern established by the 2024 acquisition of Valinor Pharma and Movantik, as Grünenthal continues to consolidate established therapeutic products. The move signals a broader trend of mid-sized pharma firms acquiring mature assets to bolster commercial scale.
Operators in the pharmaceutical space should monitor the regulatory approval timeline for this deal, which is anticipated to finalize by early 2027. Businesses with competing assets should track Stivarga's commercial shifts as it moves from Bayer's portfolio to Grünenthal's.
The takeaway
The deal highlights the importance of timing patent-lifecycle management against the acquisition of mature products. Operators should audit their own product portfolios to identify assets nearing exclusivity loss that could be candidates for divestment or strategic partnership.
Further reading
For more on industry-wide consolidation trends, visit our Healthcare section.
Live Poll
Do you trust that pharmaceutical acquisitions of existing drugs ultimately benefit patients?
